Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$9.41
-0.6%
$9.61
$8.37
$13.14
N/A0.23189,345 shs5,612 shs
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$563.20
+1.9%
$546.58
$476.49
$1,211.20
$60.66B0.33909,114 shs191,859 shs
Shiseido Co. stock logo
SSDOY
Shiseido
$18.30
+4.6%
$16.84
$15.32
$32.17
$7.31B0.3736,092 shs13,638 shs
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$14.76
-2.5%
$14.86
$12.80
$15.53
$46.98B0.231.99 million shs399,483 shs
 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
+1.83%-1.97%-2.53%+5.82%-5.96%
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
+0.88%+0.88%+6.76%+1.13%-47.57%
Shiseido Co. stock logo
SSDOY
Shiseido
+4.57%-1.19%+11.72%+6.46%-36.37%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
+0.80%-1.94%+0.66%+9.20%+15.18%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/AN/AN/AN/AN/AN/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
4.9379 of 5 stars
4.45.01.72.32.71.71.9
Shiseido Co. stock logo
SSDOY
Shiseido
2.1139 of 5 stars
0.05.00.80.02.00.01.9
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
1.379 of 5 stars
0.03.02.50.03.10.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
0.00
N/AN/AN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
2.80
Moderate Buy$813.5747.23% Upside
Shiseido Co. stock logo
SSDOY
Shiseido
0.00
N/AN/AN/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest REGN, ALPMY, TAK, and SSDOY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/30/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Argus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold
6/9/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$950.00 ➝ $800.00
6/5/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$633.00 ➝ $560.00
6/2/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$700.00 ➝ $650.00
6/2/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$800.00 ➝ $600.00
6/2/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOverweight ➝ Overweight$958.00 ➝ $755.00
5/30/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy
5/30/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeModerate Buy ➝ Hold$662.00
5/30/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeOverweight ➝ Equal Weight$700.00 ➝ $580.00
5/27/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Sector Perform$943.00 ➝ $662.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$12.56BN/A$1.83 per share5.16$5.52 per shareN/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$14.20B4.20$46.09 per share11.99$268.50 per share2.06
Shiseido Co. stock logo
SSDOY
Shiseido
$6.55B1.12$1.08 per share17.02$10.44 per share1.75
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$4.58T0.01$3.21 per share4.72$14.39 per share1.05
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$334.93M$0.1755.6513.91N/A2.65%16.55%7.35%7/29/2025 (Estimated)
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$4.41B$39.2814.0714.532.0231.94%15.27%11.93%8/1/2025 (Estimated)
Shiseido Co. stock logo
SSDOY
Shiseido
-$68.94M-$0.07N/A22.05N/A-0.40%-0.61%-0.30%8/6/2025 (Estimated)
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$712.33M$0.2268.829.18N/A2.36%10.64%5.14%7/30/2025 (Estimated)

Latest REGN, ALPMY, TAK, and SSDOY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/1/2025Q2 2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$8.53N/AN/AN/A$3.30 billionN/A
7/30/2025Q1 2026
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.47N/AN/AN/A$7.96 billionN/A
5/12/2025Q1 2025
Shiseido Co. stock logo
SSDOY
Shiseido
$0.0569$0.06+$0.0031$0.06$1.72 billion$1.54 billion
5/8/2025Q4 2025
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.24$0.16-$0.08-$0.21$8.02 billion$7.34 billion
4/29/2025Q1 2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$8.83$8.22-$0.61$7.27$3.40 billion$3.03 billion
4/25/2025Q4 2025
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$0.1474$0.27+$0.1226$0.27$3.02 billion$3.22 billion
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
$0.353.70%N/A205.88%N/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
$3.520.64%N/A8.96%N/A
Shiseido Co. stock logo
SSDOY
Shiseido
$0.070.38%N/AN/A N/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.553.63%N/A250.00%N/A

Latest REGN, ALPMY, TAK, and SSDOY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/20/2025
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
quarterly$0.880.6%5/20/20255/20/20256/6/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
0.37
1.13
0.85
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
0.09
4.93
4.03
Shiseido Co. stock logo
SSDOY
Shiseido
0.36
1.20
0.79
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.57
1.01
0.52

Institutional Ownership

CompanyInstitutional Ownership
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
N/A
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
83.31%
Shiseido Co. stock logo
SSDOY
Shiseido
0.02%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
9.17%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astellas Pharma Inc. stock logo
ALPMY
Astellas Pharma
14,754N/AN/ANot Optionable
Regeneron Pharmaceuticals, Inc. stock logo
REGN
Regeneron Pharmaceuticals
15,106107.96 million100.39 millionOptionable
Shiseido Co. stock logo
SSDOY
Shiseido
27,908399.66 millionN/ANot Optionable
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
47,4553.18 billion3.18 billionOptionable

Recent News About These Companies

Lupin gets USFDA approval for post-eye surgery drug
FDA Approves Takeda’s Gammagard Liquid ERC
Lupin receives USFDA approval for Prucalopride Tablets
Takeda Announces New Assignments of Directors

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Astellas Pharma stock logo

Astellas Pharma OTCMKTS:ALPMY

$9.41 -0.06 (-0.58%)
As of 10:22 AM Eastern

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. Th company has a research collaboration with Vivtex Corporation to evaluate Vivtex's GI-ORIS screening and formulation platform technology to support the development of novel and oral versions of a therapeutic candidate provided by Astellas; and a partnership agreement with Roche Diabetes Care Japan Co., Ltd. to develop and commercialize integrated diabetes self-management solution. The company was founded in 1923 and is headquartered in Tokyo, Japan.

Regeneron Pharmaceuticals stock logo

Regeneron Pharmaceuticals NASDAQ:REGN

$563.20 +10.62 (+1.92%)
As of 10:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.

Shiseido stock logo

Shiseido OTCMKTS:SSDOY

$18.30 +0.80 (+4.57%)
As of 07/9/2025 03:58 PM Eastern

Shiseido Company, Limited engages in the production and sale of cosmetics in Japan and internationally. The company offers fragrances; and skincare and makeup products. It also engages in the restaurant and food, and retail businesses; and operates beauty salons. In addition, the company operates and supports SABFA, a professional hair makeup training school. Further, it offers childcare facilities. The company sells its products through department, specialized cosmetic, drug, and general merchandise stores. Shiseido Company, Limited was founded in 1872 and is headquartered in Tokyo, Japan.

Takeda Pharmaceutical stock logo

Takeda Pharmaceutical NYSE:TAK

$14.76 -0.37 (-2.47%)
As of 10:38 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.